Certara Q3 revenue rises 4%, beats estimates

By Reuters News


Overview

  • Drug development software firm's Q3 revenue rose 4%, beating analyst expectations

  • Adjusted EPS for Q3 met analyst expectations

  • Company narrowed 2026 revenue growth outlook to 2%-3%


Outlook

  • Certara narrows 2026 full-year revenue growth outlook to 2% to 3%

  • Company expects 2026 software revenue growth above total revenue growth range

  • Certara updates 2026 adjusted diluted EPS outlook to $0.31 to $0.34


Result Drivers

  • SOFTWARE GROWTH - Software revenue rose 11% organically, marking the first double-digit quarterly increase in two years, according to CEO Jon Resnick

  • SERVICES WEAKNESS - Services revenue declined 2% year-over-year as the company works to convert its pipeline into bookings and revenue

  • OPERATING ACTIONS - Company said margin improvement reflected initial benefits from operating actions implemented in the first half, per Interim CFO Faiz Mohammed


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$94.90 mln

$92.87 mln (11 Analysts)

Q3 Adjusted EPS

Meet

$0.09

$0.09 (10 Analysts)

Q3 Adjusted Net Income

$13.50 mln

Q3 Net Income

$5.59 mln

Q3 Adjusted EBITDA

$30.20 mln

Q3 Pretax Loss

$1.18 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the software peer group is "buy."

  • Wall Street's median 12-month price target for Certara, Inc. is $9.00, about 18.8% below its November 4 closing price of $11.09

  • The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 20 three months ago


Reuters Recommended Reads

  • Nov 4 - HubSpot Q3 revenue beats estimates driven by subscription growth

  • Nov 4 - Figma's Q3 revenue jumps 43% and beats estimates; raises FY revenue outlook

  • Nov 3 - Varonis Q3 revenue rises 17%, beats analyst expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.